... A web-based Atlas of Patient-Derived Xenografts of cancer patients:A resource of MURAL PDX data
Home
Search by IDs Search by Gene
Browse
With gene expression Without gene expression Mutation & CNV Plot
Patient Tumor & Clinical details PDX & PDXBiomarker details
View & Update
Statistics



PDX model details

PDX ID 201.2A Cx
Host Strain(and Source) NSG
Source: Monash University
Host Strain Immune system Humanized NO
Host Type Castrate
Graft Site Subcutaneous
Current Generation
(* indicates number of generations grown in Castrate host)
 26 (19*)
Average PDX Generation Time (days +/- SEM) 44 ± 2
Tumor preparation Tumor solid
Tumor Characterization Technology Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq
Tumor confirmed not to be of Mouse/EBV origin Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC
Passage QA performed Routine QA every 2-3 passages
Associated meta data
PDX model availability Yes (fixed, frozen or cryopreserved tissue)
Governance restriction for distribution Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements
Pubmed ID 34413304; 30049486
Markers 201.2A Cx
AR N
PSA N
PSMA N
NE Y
ERG N
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.

PDX ID Gene Symbol CNV Log2 CNV Copy CNV Call Experiments name Platform Reference genome
201.2A Cx AKT1 -0.91813 1.05839 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx APC -1.05096 0.965294 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx ARID4A -0.99595 1.00281 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CDKN1B -1.0658 0.955415 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CDKN2A -1.00407 0.997183 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CHD1 -1.05096 0.965294 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CHD7 0.558955 2.9464 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx CUL3 -1.0749 0.949408 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx ERF -0.918781 1.05791 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx MBD1 -1.00125 0.999134 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx MYC 0.960313 3.89146 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx PIK3CB 0.505852 2.83992 gain MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx PTEN -14.1286 0.00011166 homdel MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx PTEN -1.24069 0.84634 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx RB1 -26.4693 0.0000000215 homdel MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx SMAD2 -1.00125 0.999134 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx SMARCAD1 -1.01026 0.992914 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx SUFU -1.24069 0.84634 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx TCERG1 -0.999305 1.00048 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx TP53 -0.845146 1.11331 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx USP28 -1.00272 0.998116 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19
201.2A Cx ZNRF3 -0.938991 1.0432 loss MURAL Prostate Cancer PDX collection Targeted Twist Panel hg19

Clinical Information

Sample Number 201.2A
Sample Site Lung
Sample source Autopsy
Pathology Tumor Diagnosis Adenocarcinoma
Gleason Score None
Primary Gleason Score None
Secondary Gleason Score None
Tertiary Gleason Score None
ISUP Grade Group
Tumor Grade
D'Amico Risk Classification
Tumor Volume (in cc) 0.0
Treatment Prior to Specimen Collection ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide

Patient Information

Patient Number 201
Sex Male
Diagnosis Prostate Cancer
PSA at diagnosis (ng/mL) NA
Consent to share data

Patient Tumor Collection (Current Model)
Tumour sample ID 201.2A
Patient Age (binned in 5 year age groups) 70-74
This heatmap displays the mutations of curated sequence variants.
Download The Mut plot is not shown
PDX ID Gene Symbol Depth ALT_FREQ Consequence Exon GnomAD_AF CADD_PHRED Clinvar_clnsig Platform Experiments Name Reference Library Type Instrument Type
201.2A Cx CTNNB1 474 1.0 missense_variant '3/15 . 29.9 Pathogenic/Likely_pathogenic,_other Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx AR 255 1.0 missense_variant '8/8 . 25.3 Pathogenic Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx TP53 258 1.0 missense_variant '8/11 1.22E-05 25.3 Conflicting_interpretations_of_pathogenicity Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx ZMYM3 184 0.98 frameshift_variant '8/25 . . - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx MUTYH 608 0.5 missense_variant '13/16 0.0007924 20.7 Conflicting_interpretations_of_pathogenicity Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx CACNA1H 585 0.5 missense_variant '9/35 8.90E-05 5.716 Uncertain_significance Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx MSH2 280 0.49 missense_variant '16/16 6.12E-05 27.7 Uncertain_significance Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500
201.2A Cx ARID1A 623 0.32 frameshift_variant '3/20 . . - Targeted Twist Panel MURAL Prostate Cancer PDX collection hg19 paired NextSeq 500